Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-19

Study Completion Date

2022-11-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer is the most common cancer in women in Europe. Therefore, breast cancer has become a chronic disease and patients need to learn to live with it as well as with the adverse effects related to the disease itself or to the therapies used.

As noted in the third "Plan cancer", pain is a major criterion in the quality of life of patients treated for breast cancer.

Neuropathic pain was defined in 2011 by the international Association for the Study of Pain (I.A.S.P.) as the direct result of a lesion or disease affecting the somato-sensory system.

Surgical treatment is often the first treatment of breast cancer. It can be conservative by performing a partial mastectomy (lumpectomy or quadrantectomy) or non-preservative by total mastectomy.

Intercostobrachial neuralgia (NICB) or Post mastectomy painful Syndrome (MPRR) was first described by Wood in 1978 as "chronic pain beginning immediately or early after a mastectomy" Or a lumpectomy affecting the anterior thorax, armpit and/or arm in its upper half. These post-surgical pains are related to a lesion of the nerves in the breast area.

In particular, the intercostobrachial nerve can be severed, stretched or crushed during surgery.

Post-operative neuropathic pain in patients with breast cancer is underdiagnosed either by general practitioner or in a specialized environment.

The diagnosis of neuropathic pain is performed during examination and clinical examination. Several scales allow to detect neuropathic pain but only the DN4 is recognized to be the most specific and sensitive scale.

Patients do not always express this pain. They do not always reconcile with the surgery. Either because the pain occurs a long time after the surgery, or they find it normal to get hurt. These diagnostic difficulties cause a delay in setting up a suitable analgesic treatment.

However, neuropathic pain responds poorly to common analgesics. Diagnosis, evaluation and early management of neuropathic pain are a priority in order to avoid their chronicization, to improve the quality of life of patients with breast cancer and to enable them to return to work quickly.

We therefore assume that the diagnosis of early neuropathic pain at 2 months of surgery associated with initiation of appropriate topical treatment without the systemic effects of conventional oral treatments, would reduce the incidence of Chronic neuropathic pain 6 months after surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pregabalin in Treating Women With Hot Flashes

NCT00702949

Breast Cancer Hot Flashes

COMPLETED PHASE3

Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain

NCT02240199

Post-mastectomy Pain Syndrome Chronic Post-surgical Pain

COMPLETED PHASE3

The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study

NCT00852683

Breast Cancer Surgery Post Operative Pain

COMPLETED PHASE3

Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery

NCT00785382

Postoperative Pain

COMPLETED PHASE4

Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery

NCT03216187

Persistent Postoperative Pain

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Patient

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicenter, open, randomized study

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm CAPSAICINE topical

Application of capsaicin patches at 8% on the painful area

1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later.

Group Type EXPERIMENTAL

Capsaicin

Intervention Type DRUG

Application of capsaicin patches at 8% on painful area

Arm PREGABALINE

Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.

An interval of 3 to 7 days must be observed between each dose increase.

Group Type ACTIVE_COMPARATOR

Pregabalin

Intervention Type DRUG

Taking Pregabalin tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capsaicin

Application of capsaicin patches at 8% on painful area

Intervention Type DRUG

Pregabalin

Taking Pregabalin tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

qutenza EU/1/09/524/001 Lyrica

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female who had first breast cancer surgery, regardless of the type of surgery
* Age ≥ 18 years
* Healthy, non-irritated skin on painful areas to treat
* During the inclusion visit to M4 post surgery, neuropathic pain of the breast and / or axillary area corresponding to inter-brachial neuralgia with a DN4≥4 score.
* Obtaining the signed written consent of the patient
* Major patient affiliated to a social security scheme

Exclusion Criteria

* Contraindications specific to the treatments studied : capsaicine and pregabalin
* Diabetic patient
* Previous treatment with capsaicin or pregabalin
* Opioid treatment\> 80 mg / day (oral morphine equivalent) in progress- Topical treatment of pain between surgery and inclusion visit
* Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 90 mmHg) or recent history (\<3 months) of cardiovascular events (stroke, heart attack, pulmonary embolism)
* Creatinine clearance (CLcr) \<60mL / min according to the Cockcroft-Gault formula
* Pregnant woman, likely to be pregnant or breastfeeding
* Persons deprived of their liberty or guardianship (including curators),
* Impossibility of submitting to the medical follow-up of the test for geographical, social or psychological reasons

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No